Glaxo, Novartis Keep Deal-Making on Target

The specter of the megamerger was again haunting the pharmaceuticals sector. But if talk of Pfizer's $100 billion approach to buy AstraZeneca gave investors a chill, Tuesday's series of deals between Novartis, GlaxoSmithKline and Eli Lilly could act as an exorcism.

Given the sector's past, shareholders are rightly wary of deals that create unwieldy behemoths and disrupt crucial research-and-development efforts.

Instead,...

RELATED VIDEO

Novartis and Glaxo Deal Reshapes Pharma Industry

Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. Hester Plumridge explains why the Swiss company is doing these deals now and what this means for the pharmaceutical industry.